5. Conclusion
We demonstrated in our cohort that low EVI1 expression at diagnosis predicted poor outcomes in pediatric Ph-negative BCP-ALL patients receiving chemotherapy only, which was validated by TARGET ALL Expansion (Phase 2) project cohort. It implied the necessity to test EVI1 transcript at diagnosis for stratification. The current result needs to be confirmed in other cohort and the prognostic impact of EVI1 expression in BCP-ALL patients receiving allogeneic stem cell transplantation remains to be evaluated. Furthermore, prospective multicenter trial is warranted, and the mechanism of the effect need be investigated.